Table 3.
Menarche and fertility ● Do unique hormonal or epigenetic mechanisms link early and late menarche and polycystic ovary syndrome with future CVD risk? ● Are assisted reproductive technologies causally linked to CVD or simply a signal for underlying infertility and associated shared risk factors with CVD? |
Pregnancy and adverse pregnancy outcomes ● What are the shared and unique pathophysiologic pathways underlying the various adverse pregnancy outcomes? How do long-term cardiometabolic implications differ across different adverse pregnancy outcomes and their subtypes? ● What are the key novel mechanisms and pathways linking adverse pregnancy outcomes with later-life CVD risk? ● Are associations between parity and CVD risk driven by socio-behavioral or biological effects (or both)? ● What is the protective mechanism of breastfeeding against CVD, and can this be leveraged therapeutically? |
Menopause ● Do cardiometabolic changes during the menopause transition independently predict future CVD? ● What are the mechanisms linking premature age of menopause and vasomotor symptoms with CVD? ● What are the relationships among clonal hematopoiesis of indeterminate potential, premature menopause, and CVD? ● Is there a role for exogenous estradiol in cardiometabolic and lipid profile improvement in subsets of postmenopausal women? |
Overarching questions for future research ● Can reproductive history prompt targeted cardiometabolic risk-reduction approaches for primordial and primary prevention? ● Can mechanistic insights into reproductive exposures yield novel preventive strategies and therapeutics? ● How do associations between reproductive history and CVD differ across racial/ethnic groups? ● Can sex-specific cardiovascular risk prediction models effectively incorporate reproductive history to refine risk prediction? ● How can we better educate clinicians about the role of reproductive history in CVD risk? |
CVD = cardiovascular disease